Investment Bank William Blair Lowers Estimates for Illumina, PacBio | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank William Blair today lowered top-line and bottom-line estimates for Illumina and Pacific Biosciences, citing government funding worries that could impact sales of both firms' instruments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.